AKTS (Aktis Oncology) Ending Cash Position: $83.64 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AKTS Aktis Oncology Inc AKTS
12 GF Score
Price $24.07
! 1 Warning Sign
View Full Analysis

What is Aktis Oncology Ending Cash Position?

Aktis Oncology AKTS +0.04% 12 Ending Cash Position is $83.64 Mil as of Jun. 2026. GuruFocus rates AKTS with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Aktis Oncology's Ending Cash Position for the quarter that ended in Jun. 2026 was $83.64 Mil.

Aktis Oncology's quarterly Ending Cash Position increased from Dec. 2025 ($38.93 Mil) to Mar. 2026 ($372.78 Mil) but then declined from Mar. 2026 ($372.78 Mil) to Jun. 2026 ($83.64 Mil).

Aktis Oncology's annual Ending Cash Position increased from Dec. 2023 ($30.66 Mil) to Dec. 2024 ($38.31 Mil) and increased from Dec. 2024 ($38.31 Mil) to Dec. 2025 ($38.93 Mil).

Aktis Oncology Ending Cash Position Related Terms

Aktis Oncology Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Aktis Oncology's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aktis Oncology Ending Cash Position Chart

Aktis Oncology Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Ending Cash Position
129.49 30.66 38.31 38.93

Aktis Oncology Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only 111.36 181.40 38.93 372.78 83.64
AKTS
12GF Score
Aktis Oncology Inc AKTS
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aktis Oncology Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Aktis Oncology's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=38.308+0.625
=38.93

Aktis Oncology's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=372.779+-289.139
=83.64

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $83.64 Mil mean?
Aktis Oncology (AKTS) has a Ending Cash Position of $83.64 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Aktis Oncology and its competitors.
Is Aktis Oncology's Ending Cash Position too high?
Aktis Oncology's current Ending Cash Position is $83.64 Mil. Overall, Aktis Oncology has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Aktis Oncology's Ending Cash Position compare to ABSI and MNKD?
Aktis Oncology's Ending Cash Position of $83.64 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Aktis Oncology and its competitors. Aktis Oncology's current Ending Cash Position is $83.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aktis Oncology stock overvalued right now?
Aktis Oncology (AKTS) has a current Ending Cash Position of $83.64 Mil. The current Ending Cash Position is $83.64 Mil. Aktis Oncology's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Aktis Oncology (AKTS), the current Ending Cash Position is $83.64 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aktis Oncology Business Description

Address 17 Drydock Avenue, Suite 17-401, Boston, MA, USA, 02210
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
12GF Score

Get the complete analysis for AKTS

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.07
Price